A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses - Regional Cancer Care Associates LLC

Clinical Trials

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia
Locations
Hackensack
Sponsor
Ariad
Protocol Number
AP24534-14203
Cancer Diagnosis
To Learn More Call
201-510-0910